Boston Scientific to Update Pacemakers in Recall, FDA Says

Dow Jones
05/08
 

By Kelly Cloonan

 

The Food and Drug Administration said Boston Scientific will upgrade certain pacemakers to a new software as part of a recall.

Boston Scientific issued a letter to affected customers recommending all of its Accolade pacemakers and cardiac resynchronization therapy pacemakers get upgraded to Brady SMR6 software, the FDA said. The correction aims to resolve risks that come with an earlier version of the software, including misinterpretation of test results in the presence of a magnet.

Boston Scientific also identified a potential risk that the old software could cause a prolonged voltage recovery state which may lead to a stuck battery status or diagnostics in some patients, the FDA said.

As of March 18, Boston Scientific has reported four deaths and 2,557 serious injuries associated with this issue, the FDA said.

"The FDA has identified this recall as the most serious type. This device may cause serious injury or death if you continue to use it without correction," the agency said.

 

Write to Kelly Cloonan at kelly.cloonan@wsj.com

 

(END) Dow Jones Newswires

May 07, 2026 19:05 ET (23:05 GMT)

Copyright (c) 2026 Dow Jones & Company, Inc.

應版權方要求,你需要登入查看該內容

免責聲明:投資有風險,本文並非投資建議,以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請,作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考,不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證,投資者應自行研究並在投資前尋求專業建議。

熱議股票

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10